Adalimumab Treatment in Biologically Naïve Crohn’s Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement
Background. Adalimumab (ADA) is effective for patients with Crohn’s disease (CD). However, there have been few reports on ADA therapy with respect to its relationship with pathologic findings and drug efficacy in biologically naïve CD cases. Methods. Fifteen patients with active biologically naïve...
Saved in:
Main Authors: | Tsutomu Mizoshita, Satoshi Tanida, Hironobu Tsukamoto, Keiji Ozeki, Takahito Katano, Hirotaka Nishiwaki, Masahide Ebi, Yoshinori Mori, Eiji Kubota, Hiromi Kataoka, Takeshi Kamiya, Takashi Joh |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2014-01-01
|
Series: | Gastroenterology Research and Practice |
Online Access: | http://dx.doi.org/10.1155/2014/687257 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
MUC2 expression modulates immune infiltration in colorectal cancer
by: Christophe M. Raynaud, et al.
Published: (2025-01-01) -
Adalimumab: Another Medication Related to Osteonecrosis of the Jaws?
by: Andrea Cassoni, et al.
Published: (2016-01-01) -
MUC5B modulation of early oral biofilm glucose metabolism
by: Carolina Robertsson, et al.
Published: (2025-02-01) -
A Meta-Analysis of Adalimumab for Fistula in Crohn’s Disease
by: Yin-mei Fu, et al.
Published: (2017-01-01) -
Tuberculosis of the tongue in a patient under treatment with adalimumab
by: Cintia Mussi Milani, et al.
Published: (2024-12-01)